Anavex Life Sciences Corp (AVXL)

[Investor2014]

Excellent work tracing the patent history.

So we have a patent granted on 2-73 good till 2035!

Given this

Therefore, if the prior art [Greek patent 1002616] teaches the identical chemical structure, the properties applicant discloses and/or claims [in 12/522761] are necessarily present.” In other words, even though the original Greek patent does not mention anti-cancer, anti-metastatic, and anti-inflammatory activity, these properties must be present because the compound is present.

Does it in practice matter that Anavex cannot claim same molecule for AD? After all the molecule is protected, for other indications, and presumably no one can copy 2-73 and start using it for AD without infringing the patent that Anavex hold, since the molecule's properties that applies to AD must necessarily be present?

Of course if a patentable variant of 2-73 could be invented still effective for AD, then that could be competition. The saving grace we must hope is 3-71 being even better than 2-73 and patent protected by U.S. Patent No. 8,673,931